Evidence map›Paper›PMID 41879713›Full record

ArticleBlood advances2026

Real-world experience with tabelecleucel within and beyond the approval label.

Kiavasch Mohammad Nejad Farid, Florian Kocher, Tobias Arnold, Josia Fauser, Elisa Henze, Christian Schultze-Florey, Carmen Diana Herling, Vladan Vučinić, Christian Reicherts, Matthias Stelljes and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Kiavasch Mohammad Nejad FaridDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0009-0006-9361-4467
Florian KocherDepartment of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Tobias ArnoldDepartment of Hematology, Oncology and Immunology, University Hospital of Gießen and Marburg, Gießen, Germany.
Josia FauserDepartment of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-1280-7464
Elisa HenzeDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-2854-4785
Christian Schultze-FloreyDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-3307-2639
Carmen Diana HerlingDepartment of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.ORCID 0009-0000-4223-5316
Vladan VučinićDepartment of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.ORCID 0000-0002-8398-285X
Christian ReichertsDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Matthias StelljesDepartment of Medicine A, University Hospital Münster, Münster, Germany.ORCID 0000-0002-9331-5145
Raphael StadelmannDivision of Hematology, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Christof ScheidDepartment I of Internal Medicine, Medical Faculty at University Hospital of Cologne, University of Cologne, Cologne, Germany.
Udo HoltickDepartment I of Internal Medicine, Medical Faculty at University Hospital of Cologne, University of Cologne, Cologne, Germany.
Stavroula Masouridi-LevratDivision of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
Marc WehrliDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Urban NovakDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Paul SchnitzlerDepartment of Infectious Diseases and Virology, University Hospital Heidelberg, Heidelberg, Germany.
Chiraz Ben-SalahDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
Isabelle KrämerDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
Anita SchmittDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
Carsten Müller-TidowDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0002-7166-5232
Thomas LuftDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
Peter DregerDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
Michael SchmittDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty at University of Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractTabelecleucel (tab-cel) is an allogeneic Epstein-Barr virus (EBV)-specific T-cell therapy approved in the European Union for relapsed or refractory (R/R) EBV-associated posttransplantation lymphoproliferative disorder (PTLD) after rituximab or immunochemotherapy failure. Despite its promise as the first approved option for treating the disorder, real-world evidence remains limited. The aim of this study was to investigate the scope of use and outcomes of tab-cel treatment in the real-world setting across Germany, Austria, and Switzerland. Eleven patients with EBV+ PTLD or other EBV-associated lymphoproliferative disorders (LPD) from 9 academic centers were included for a detailed analysis of baseline characteristics and survival parameters. Of these, 8 patients with PTLD (6 after solid organ transplantation and 2 after allogeneic hematopoietic cell transplantation) and 3 patients with EBV-associated LPDs were treated with a median of 2 cycles of tab-cel (range, 1-3). After a median follow-up of 15.1 months, 6 of 11 (55%) patients remained alive. Initially, 7 of 11 patients (64%) achieved an objective response, with best response occurring at a median of 31 days after the first tab-cel infusion (ie, end of cycle 1). Relapse and progression after tab-cel occurred in 7 of 11 (64%) patients. The estimated median overall survival was 13.4 months (confidence interval, 4.4-14.7), likely because of successful subsequent salvage treatments. Immunotherapy-related adverse events were rare. Tab-cel showed efficacy and low toxicity in patients with R/R PTLD/LPD, a vulnerable cohort of immunodeficient or patient who underwent transplantations. These real-world data help elucidate the optimal integration of tab-cel in the management of R/R PTLD.

Indexed as

Epstein-Barr Virus InfectionsLymphoproliferative DisordersAdultAgedFemaleHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHumansMaleMiddle AgedT-LymphocytesTreatment Outcome

Identifiers

PMID41879713
PMCPMC13261886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.